APONTIS PHARMA AG

Latest Results (09.11.2025):

APONTIS PHARMA AG's half-year financial report for 2025 highlights strong revenue momentum in its pharmaceutical segments, with notable performance improvements in both the first and second quarters of 2025. The company recorded significant growth in its single-pill combinations, seeing remarkable increases in Q1 followed by continued positive developments in Q2. However, this revenue expansion was accompanied by a decline in consolidated EBITDA when compared with the first half of 2024, amidst ongoing strategic investments and portfolio enhancements.

Revenue Performance

In the first quarter of 2025, APONTIS PHARMA AG registered a 28% increase in revenue from its single-pill combinations. This momentum carried into the second quarter, with total revenue rising by 3% compared to the same quarter in the previous year. Overall, the first half of 2025 saw total revenue grow by EUR 3.3 million, or 14.6%, while revenue from single pill combinations increased by EUR 1.1 million (6.2%).

EBITDA Update

Despite the revenue gains, the consolidated EBITDA for the first half of 2025 declined by EUR 0.6 million to EUR 1.5 million, compared with EUR 2.1 million in the same period of 2024, indicating cost pressures amid restructuring and strategic investments.

Product Portfolio Expansion

APONTIS PHARMA AG strengthened its position by expanding its product portfolio with the addition of two high blood pressure medications, CandeInda and TelmiInda. These single-pill combinations are part of the company’s strategy to broaden its range and tap into the high patient potential in hypertension and related indications.

Strategic and Market Developments

The report also notes significant structural changes, including the planned integration into the Zentiva Group following the share transfer resolution. This move is expected to drive future growth, alongside ongoing collaborations, such as the promising sales cooperation with Novartis for asthma products.